Skip to content

Trial to evaluate the safety and performance of Deumavan® at Radiodermatitis

Trial to evaluate the safety and performance of Deumavan® at Radiodermatitis - Deumavan_RD01

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00023145
Enrollment
60
Registered
2020-09-24
Start date
2020-09-28
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiodermatitis

Interventions

Group 1: Application of Deumavan® according to a standardized procedure, 3 times a day for the duration of the radiation therapy and during the follow-up, weekly assessment of the radiation dermatitis

Sponsors

Kaymogyn GmbH
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Male and female patients aged 18 years - Presence of an anogenital tumor (anal canal and anal rim carcinoma, vulvar carcinoma, penile carcinoma, rectum carcinoma of the lower third or with involvement of the sphincter muscle) with an indication for definitive or adjuvant radiation of the tumor and / or the pelvic or inguinal lymphatic drainage pathways - Target total radiation dose = 40 Gy - Life expectancy> 6 months - Signed declaration of consent before starting the study

Exclusion criteria

Exclusion criteria: - Pregnant or breastfeeding women - Previous radiation in the current radiation area - Participation in a clinical trial within the last 30 days - Hypersensitivity or allergy to one or more of the ingredients in Deumavan® - Patients with existing high-grade skin diseases in the radiation area that require treatment - Patients incapable of giving consent (according to MPG Section 20, Paragraph 2, Clause 1, No. 1)

Design outcomes

Primary

MeasureTime frame
The doctor in charge assesses the presence of radiodermatitis at the time of the examination, taking into account the severity using the CTCAE criteria (CTCAE version 5.0). On the one hand, the frequency of occurring radiodermatitis will be considered and, on the other hand, its severity.

Secondary

MeasureTime frame
- Detection of skin-associated (S) AEs - Recording of product-related (S) AE, incidents - Assessment of symptoms and impairment of quality of life (assessment of radiation-induced skin reaction) - Assessment of the tolerability of Deumavan® by the patient on the basis of school grades - Assessment of the effectiveness of Deumavan® with regard to the prophylaxis and treatment of radiodermatitis by the doctor based on school grades - Changes in the CTCAE between baseline and subsequent visits - Patient compliance by keeping a diary

Countries

Germany

Contacts

Public ContactFlorian Sterzing

Praxis für Strahlentherapie

f.sterzing@strahlentherapie-kempten.de+49 (0) 831 9607074

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026